Repligen Co. (NASDAQ:RGEN) Receives $194.00 Average Price Target from Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $194.00.

A number of research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and lowered their target price for the company from $180.00 to $155.00 in a research note on Wednesday, June 26th. Guggenheim assumed coverage on shares of Repligen in a research note on Tuesday, June 18th. They set a “neutral” rating on the stock. Finally, JPMorgan Chase & Co. lowered their target price on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd.

Repligen Trading Up 0.7 %

Shares of RGEN stock opened at $132.36 on Friday. Repligen has a 1 year low of $110.45 and a 1 year high of $211.13. The firm has a fifty day moving average price of $136.09 and a 200-day moving average price of $166.88. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. The company has a market cap of $7.40 billion, a price-to-earnings ratio of 529.46, a PEG ratio of 4.44 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The firm had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter last year, the firm posted $0.64 EPS. The firm’s quarterly revenue was down 17.1% compared to the same quarter last year. As a group, equities analysts predict that Repligen will post 1.46 earnings per share for the current year.

Insider Activity

In other news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares in the company, valued at approximately $27,456,162.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares in the company, valued at approximately $27,456,162.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Martin D. Madaus bought 1,615 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were acquired at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the transaction, the director now directly owns 4,613 shares in the company, valued at approximately $576,348.22. The disclosure for this purchase can be found here. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Hedge funds have recently added to or reduced their stakes in the company. YHB Investment Advisors Inc. bought a new position in Repligen during the 1st quarter valued at about $26,000. Lazard Asset Management LLC grew its holdings in Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 136 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares during the last quarter. Principal Securities Inc. bought a new position in Repligen during the 4th quarter valued at about $48,000. Finally, CWM LLC grew its holdings in Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 60 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.